Emergex

Britain’s Emergex Vaccines announced last week that it has received Swiss regulatory approval to launch Phase 1 trials of its T cell dengue vaccine candidate, PepGNP-Dengue.

The company raised $22 million last year to advance its synthetic T cell vaccine portfolio (delivered using a thermostable microneedle patch), including candidates for Covid-19, dengue and pandemic influenza.

Mentions:

The state of the hunt:

WHO issued its first EUL for a Covid-19 vaccine in recent days while Britain and the EMA authorized an additional jab and China and India cleared their first shots.
  Both Bharat Biotech and Pfizer claimed their respective vaccines are effective against newly identified SARS-CoV-2 variants.
  SII pledged to sell an initial 100 million doses to India at a “special price” of $2.74 each.

 

Vaccines


Approved or authorized…

Britain’s Emergex Vaccines announced last week that it has raised $11 million from “new and existing investors” to develop its synthetic T-cell vaccines (delivered using a thermostable microneedle patch), including candidates for Covid-19, dengue and pandemic influenza. The company raised $11 million in Series A financing in January, in part to advance its Phase 1 dengue shot.

New Delhi-based Panacea Biotec announced last week that DengiAll, its tetravalent recombinant chimeric vaccine candidate against dengue fever, has completed Phase 1/2 trials. After a single dose of the live-attenuated vaccine, “more than 80% of the participants showed more than a [trivalent] response and ~95% showed a multivalent response,” the company’s press release said.

Brazil’s Instituto Butantan, Britain’s Emergex, Merck, Serum Institute of India and Japan’s Takeda are also in…


The state of the hunt: 

Gilead’s remdesivir became the first Covid-19 therapeutic to score Emergency Use Authorization from the U.S. FDA. Inovio, J&J, Moderna and Oxford University have signed new deals with manufacturing partners for their vaccine candidates. The inactivated vaccine from CNBG’s Wuhan subsidiary has entered Phase 2, with its ongoing Phase 1 trial showing “good safety” to date.

 

Vaccines

Our Covid-19 Vaccine Dashboard provides comprehensive…

Britain’s Emergex Vaccines announced last week that it has raised more than $11 million in Series A financing to advance Phase 1 trials of its dengue vaccine candidate. The funding will also support the company’s universal influenza and filovirus programs through preclinical and early clinical trials, the press release said.

Britain’s Emergex Vaccines announced last week that it has completed preclinical testing of its dengue vaccine candidate and will now advance to human studies. The shot may also protect against other flaviviruses, including Zika and yellow fever, according to the press release.

The company also announced separately this week that it has applied its synthetic “set-point” technology for the first time to a bacterial vaccine candidate by generating a human-specific peptide library of…

Britain’s Emergex Vaccines announced last week an agreement with Singapore’s Institute of Molecular and Cell Biology to develop a vaccine against viruses that cause hand, foot and mouth disease in humans—including coxsackieviruses and enterovirus 71.

According to the press release, Emergex uses fully synthetic components to develop vaccines that are delivered via a novel microneedle skin patch and require no refrigeration.

The company also has a Flavivirus candidate against…